Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

NCT00025662 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

NIH

Sponsor class

Conditions

Graft vs Host Disease
Myelodysplastic Syndromes
Leukemia
Leukemia, Myeloid
Leukemia, Myelomonocytic, Chronic
Leukemia, Lymphocytic
Lymphoma
Lymphoma, Mantle-cell
Lymphoma, Non-Hodgkin
Hodgkin Disease

Interventions

DRUG: RFT5-SMPT-dgA
DRUG: Isolex system

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)